We are live on ! Find out more
AUTL

Autolus Therapeutics

69 hedge funds and large institutions have $169M invested in Autolus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

31% more capital invested

Capital invested by funds: $129M → $169M (+$39.9M)

10% more funds holding

Funds holding: 6369 (+6)

4.29% more ownership

Funds ownership: 33.82%38.11% (+4.3%)

Holders
69
Holders Change
+6
Holders Change %
+9.52%
% of All Funds
1.2%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
22
Reduced
13
Closed
17
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Nomura Holdings
76
Nomura Holdings
Japan
-$165K -30,000 Closed
Two Sigma Advisers
77
Two Sigma Advisers
New York
-$80K -13,900 Closed
N
78
Natixis
France
-$72K -12,600 Closed
Victory Capital Management
79
Victory Capital Management
Texas
-$34K -6,014 Closed
SFS
80
Sowell Financial Services
Arkansas
-$8K -1,500 Closed
TCWM
81
Total Clarity Wealth Management
Illinois
-$6K -1,000 Closed
Royal Bank of Canada
82
Royal Bank of Canada
Ontario, Canada
-$1.34K -216 -78%
Bank of Montreal
83
Bank of Montreal
Ontario, Canada
-$1K -145 Closed
Barclays
84
Barclays
United Kingdom
-$217 -35 -39%
SOW
85
State of Wyoming
Wyoming
+$242 +39 New

AUTL Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2021, worth a combined $169M — up 31% from $129M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new AUTL positions and 17 closed out — a net gain of 6 holders — while 22 added to existing stakes and 13 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $16.9M. The largest seller was Capital International Investors, exiting entirely with an estimated $13M sold.

  • 69 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2021, up from 63 in Q1 2021.
  • Funds reported $169M of Autolus Therapeutics stock for Q2 2021, up 31% quarter-over-quarter.
  • 23 funds opened new Autolus Therapeutics positions in Q2 2021 and 17 closed out, a net change of +6 holders.
  • The largest Autolus Therapeutics buyer in Q2 2021 was Citadel Advisors, an estimated $16.9M added.
  • The largest Autolus Therapeutics seller in Q2 2021 was Capital International Investors, an estimated $13M sold.

Based on aggregated 13F filings for Q2 2021.